Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Total Non-Current Liabilities: 2020-2021

Historic Total Non-Current Liabilities for Protagonist Therapeutics (PTGX) over the last 2 years, with Sep 2021 value amounting to $43.4 million.

  • Protagonist Therapeutics' Total Non-Current Liabilities fell 8.76% to $43.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $43.4 million, marking a year-over-year decrease of 8.76%. This contributed to the annual value of $44.7 million for FY2020, which is N/A change from last year.
  • According to the latest figures from Q3 2021, Protagonist Therapeutics' Total Non-Current Liabilities is $43.4 million, which was down 7.01% from $46.7 million recorded in Q2 2021.
  • Protagonist Therapeutics' 5-year Total Non-Current Liabilities high stood at $57.4 million for Q2 2020, and its period low was $38.6 million during Q1 2021.
  • Moreover, its 2-year median value for Total Non-Current Liabilities was $45.7 million (2020), whereas its average is $46.4 million.
  • Data for Protagonist Therapeutics' Total Non-Current Liabilities shows a maximum YoY fell of 18.71% (in 2021) over the last 5 years.
  • Protagonist Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $44.7 million in 2020, then decreased by 8.76% to $43.4 million in 2021.
  • Its last three reported values are $43.4 million in Q3 2021, $46.7 million for Q2 2021, and $38.6 million during Q1 2021.